{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:07:51Z","timestamp":1793351271740,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clgc.2025.102313","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T19:00:29Z","timestamp":1738695629000},"page":"102313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Gu\u00e9rin\u2013Unresponsive High-Risk Non\u2013Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review"],"prefix":"10.1016","volume":"23","author":[{"given":"Girish S.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H.","family":"Abbosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Kyung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Hyeon","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Benoit","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire M.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Burcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102313_bib0001","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102313_bib0002","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4111\/icu.20230042","article-title":"Treatment strategies for the bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"64","author":"Jeong","year":"2023","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0005","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1200\/JCO.2009.23.6901","article-title":"Bladder cancer: narrowing the gap between evidence and practice","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0006","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.euo.2023.03.006","article-title":"The pursuit of intravesical and systemic therapies in non-muscle-invasive bladder cancer: challenges and opportunities","volume":"6","author":"Ghali","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0007","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Non-muscle-invasive bladder cancer: an overview of potential new treatment options","volume":"39","author":"Shore","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0008","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00345-021-03666-w","article-title":"BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?","volume":"39","author":"Lebacle","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0009","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/iju.13509","article-title":"Prediction models for progression of non-muscle-invasive bladder cancer: a review","volume":"25","author":"Fujii","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0011","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0013","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0014","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2025.102313_bib0015","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","article-title":"Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients","volume":"61","author":"Hautmann","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0017","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","article-title":"CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0018","first-page":"e120","volume":"206","author":"Gurram","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0019","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0020","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0021","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clgc.2025.102313_bib0022","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Heyne","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0023","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1002\/cncr.33792","article-title":"The impact of the social construct of race on outcomes among bacille Calmette-Gu\u00e9rin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting","volume":"127","author":"Lawler","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2025.102313_bib0024","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jval.2020.04.1812","article-title":"PCN356 real-world evidence on patients with non-muscle invasive bladder cancer treated with BCG therapy","volume":"23","author":"Chang","year":"2020","journal-title":"Value in Health"},{"key":"10.1016\/j.clgc.2025.102313_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12894-022-00959-z","article-title":"Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)","volume":"22","author":"Broughton","year":"2022","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0026","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/iju.14933","article-title":"Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Gu\u00e9rin treatment","volume":"29","author":"Miyake","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2025.102313_bib0027","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2022.40.28_suppl.404","article-title":"Real-world treatment patterns among patients with non-muscle invasive bladder cancer (NMIBC) treated with intravesical Bacillus Calmette-Guerin (BCG)","volume":"40","author":"Kumar","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102313_bib0028","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus calmette-gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:31:05Z","timestamp":1762551065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1558767325000151"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102313","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Gu\u00e9rin\u2013Unresponsive High-Risk Non\u2013Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102313"}}